10-Q: Regenerex Pharma Reports Increased Net Loss in Q1 2024 Amidst Ongoing Efforts to Launch Wound Care Products

Regenerex Pharma's Q1 2024 filing reveals a widening net loss and continued reliance on debt financing as the company prepares to launch its wound care products.

Summary

• Regenerex Pharma, Inc. filed its Form 10-Q for the quarter ended June 30, 2024.
• The company reported a net loss of $272,560 for the three months ended June 30, 2024, compared to a net loss of $185,575 for the same period in 2023.
• The increased loss is attributed to higher general and administrative expenses, including payroll, lease costs, and accounting fees.
• The company has an accumulated deficit of $5,888,410 as of June 30, 2024, and excess liabilities over assets of $4,313,389, raising concerns about its ability to continue as a going concern.
• Regenerex is focused on developing and marketing wound care healing products and is currently negotiating managed care agreements and distribution deals.
• The company's primary sources of liquidity are notes payable and raising equity capital, which are currently insufficient.
• Management plans to actively seek capital to enable the company to add new products and/or services to ultimately achieve profitability.
• The company expects to launch its sales initiative during the third quarter of its fiscal year ending March 31, 2025.
• The company is working to have its plant facility certified by the FDA.
• The company is negotiating with several distributors in various Middle Eastern countries to provide the company's products.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with increasing losses and doubts about the company's ability to continue as a going concern. While there are positive aspects like the planned product launch and efforts to secure funding, the overall sentiment is negative due to the company's financial instability.

Positives

• The company is actively developing managed care agreements and distribution deals to generate revenue.
• Regenerex is preparing to launch its sales initiative in Q3 2025.
• The company has engaged into an agreement as of June 11, 2023, in the amount of $45,000, with First Forte Consultancy in the UAE to assist in meetings and road shows, introducing potential clients for distribution of the companies wound care product.
• The company has three technologies for different types of wound conditions.

Negatives

• The company reported an increased net loss of $272,560 for Q1 2024 compared to $185,575 in Q1 2023.
• The company has a significant accumulated deficit of $5,888,410.
• The company's liabilities exceed its assets by $4,313,389.
• The company's primary sources of liquidity are currently insufficient.
• The company has no revenue during the three months ended June 30, 2024 and 2023.
• The company's auditors have identified material weaknesses in internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is in doubt due to its financial condition.
• The company may need to curtail or alter its plan of operations if it cannot raise additional capital.
• The company faces risks related to COVID-19 and other future pandemics.
• The company has a limited operating history and no assurance of success or profitability.
• The company's success depends on its ability to maintain relationships, establish collaborations, and obtain additional funding.
• The company's internal controls over financial reporting were not effective as of June 30, 2024.
• The company does not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding complex and non-routine transactions.

Future Outlook

The company expects to launch its sales initiative during the third quarter of its fiscal year ending March 31, 2025 and is actively seeking capital to enable the Company to add new products and/or services to ultimately achieve profitability.

Management Comments

• Management plans to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability.
• Management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital.

Industry Context

The wound care market is growing due to the increasing prevalence of diabetes, obesity, and an aging population, creating a demand for effective and cost-efficient wound care solutions. The Affordable Healthcare Act is changing how the entire wound care system is reimbursed in the US.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific revenue figures or market share data, it's difficult to benchmark Regenerex Pharma against competitors in the wound care market.
• Companies like Smith & Nephew, Molnlycke Health Care, and 3M are major players in the advanced wound care market, but a direct comparison requires more detailed financial and operational data from Regenerex.

Related Party Transactions

• The Company purchased assets from the Companys current Chief Executive Officer (CEO) and Secretary/Treasurer.
• On June 10, 2023, the Company, has entered into an agreement with Woundcare Labs, LLC., a party related to the CFO and CEO of the Company, to lease a plant and to lease equipment in Tennessee.
• The Companys Chief Executive Officer (CFO) advanced the Company monies for operating expenses in the net amount of $1,600 and $1,485 during the three months ended June 30, 2024 and June 30, 2023.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional equity capital.
• Employees' job security is uncertain due to the company's financial instability.
• Customers may benefit from the launch of new wound care products, but the company's ability to deliver is uncertain.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company plans to actively seek capital to fund its operations and product launch.
• The company will continue to develop managed care agreements and distribution deals.
• The company expects to launch its sales initiative during the third quarter of its fiscal year ending March 31, 2025.
• The company is working to have its plant facility certified by the FDA.

Key Dates

Keywords

Regenerex Pharma, wound care, financial results, net loss, Form 10-Q, going concern, liquidity, capital resources, intellectual property, Medicaid, distribution agreements